Korro Bio, Inc. Common Stock
$13.83
-$0.24 (-1.71%)
$13.44Day Range$14.86
Key Statistics
Market Cap
$203.66M
Shares Outstanding
14.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 6, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$14.15
Day High
$14.86
Day Low
$13.44
Volume
304.7K
VWAP
$14.16
Prev Close
$14.07
Transactions
--
Acc. Volume
--
About Korro Bio, Inc. Common Stock
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
PHARMACEUTICAL PREPARATIONSSIC 283457 employees60 FIRST STREET, CAMBRIDGE, MA, 02141617-468-1999IPO Nov 6, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001703647
- Composite FIGI
- BBG00GFMTC38
- Share Class FIGI
- BBG00GFMTC47
- Ticker Root
- KRRO
- SIC Code
- 2834
About Korro Bio, Inc. Common Stock (KRRO) Stock
Korro Bio, Inc. Common Stock (KRRO) closed the 2026-09-16 session at $13.83, down 1.71% versus the previous close (-0.24). The stock opened at $14.15 and traded between $13.44 and $14.86 during that session. Session trading volume was 305K shares. The volume-weighted average price (VWAP) is $14.16.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Korro Bio, Inc. Common Stock has a market capitalization of $203.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. KRRO is listed on the XNAS exchange. The company employs approximately 57 people. Korro Bio, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2023-11-06.
On this page you can find market KRRO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.